Is homocysteine a mediator of atrial dysfunction or just another marker of endothelial dysfunction?

Europace

Volumn 10, Issue 8, 2008, Pages 899-900

  Van Wagoner, David R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE;

ANTIOXIDANT ACTIVITY; CATHETER ABLATION; EDITORIAL; ELECTRIC ACTIVITY; ENZYME ACTIVITY; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEMODYNAMICS; HYPERHOMOCYSTEINEMIA; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; RISK ASSESSMENT; STROKE;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HUMANS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 48749128765     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eun182     Document Type: Editorial

References (12)

1. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 2002;106:2854-8.
2. Wierzbowska-Drabik K, Krzeminska-Pakula M, Drozdz J, Plewka M, Trzos E, Kurpesa M et al. Enlarged left atrium is a simple and strong predictor of poor prognosis in patients after myocardial infarction. Echocardiography 2008;25:27-35.
3. Kim YM, Guzik TJ, Hua ZY, Hua ZM, Kattach H, Ratnatunga C et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005;97:629-36.
4. Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008;51:68-74.
5. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001;104:174-80.
6. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998;44:1833-43.
7. Marcucci R, Betti I, Cecchi E, Poli D, Giusti B, Fedi S et al. Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation? Am Heart J 2004;148:456-61.
8. Shimano M, Inden Y, Tsuji Y, Kamiya H, Uchikawa T, Shibata R et al. Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation. Europace 2008;10:961-66.
9. Cha TJ, Ehrlich JR, Zhang L, Shi YF, Tardif JC, Leung TK et al. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 2004;109:412-8.
10. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76.
11. Domagala TB, Lacinski M, Trzeciak WH, Mackness B, Mackness MI, Jakubowski H. The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol (Noisy-le-grand) 2006;52:4-10.
12. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008;299:2027-36.